<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00150579</url>
  </required_header>
  <id_info>
    <org_study_id>SPD465-301</org_study_id>
    <nct_id>NCT00150579</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SPD465 in Adults With ADHD</brief_title>
  <official_title>A Phase III, Randomized, Double-blind, Multi-center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of SPD465 compared to&#xD;
      placebo (a capsule with no medication in it) in the treatment of ADHD. The study will also&#xD;
      look at how SPD465 affects sleep and how the participants perceive their quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 27, 2005</start_date>
  <completion_date type="Actual">June 14, 2005</completion_date>
  <primary_completion_date type="Actual">June 14, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the ADHD-rating scale 4th Edition (ADHD-RS-IV) total score to the Endpoint assessment.</measure>
    <time_frame>Baseline, and the Endpoint (average of weeks 5, 6, 7).</time_frame>
    <description>The Endpoint is the average of the values obtained at Weeks 5, 6, and 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Clinical Global Impression of Improvement scale (CGI-I) to the Endpoint assessment.</measure>
    <time_frame>Baseline, and the Endpoint (average of weeks 5, 6, 7).</time_frame>
    <description>The Endpoint is the average of the values obtained at Weeks 5, 6, and 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Time-Sensitive ADHD Symptom Scale (TASS) score to the Endpoint assessment.</measure>
    <time_frame>Baseline, and the Endpoint (average of weeks 5, 6, 7).</time_frame>
    <description>The Endpoint is the average of the values obtained at Weeks 5, 6, and 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Brown Attention Deficit Disorder Scale (BADDS) to the Endpoint assessment</measure>
    <time_frame>Baseline, and the Endpoint (average of weeks 5, 6, 7).</time_frame>
    <description>The Endpoint is the average of the values obtained at Weeks 5, 6, and 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline in the Adult ADHD Impact Module (AIM-A) score to the Endpoint assessment</measure>
    <time_frame>Baseline, and the Endpoint (average of weeks 5, 6, 7).</time_frame>
    <description>The Endpoint is the average of the values obtained at Weeks 5, 6, and 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) at Week 1</measure>
    <time_frame>Baseline and Week 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) at Week 4</measure>
    <time_frame>Baseline and Week 4.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) at Week 7</measure>
    <time_frame>Baseline and Week 7.</time_frame>
  </secondary_outcome>
  <enrollment>240</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary diagnosis of ADHD&#xD;
&#xD;
          -  Baseline ADHD-RS-IV score &gt;= 24&#xD;
&#xD;
          -  Non-pregnant females of childbearing potential must comply with contraceptive&#xD;
             restrictions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significantly underweight or morbidly obese&#xD;
&#xD;
          -  Comorbid psychiatric diagnosis with significant symptoms such as Axis II disorders or&#xD;
             severe Axis I disorders&#xD;
&#xD;
          -  History of seizure, tic disorder, or a current diagnosis and/or family history of&#xD;
             Tourette's Disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
    <mesh_term>Adderall</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

